One of the most common and distressing symptoms of menopause are hot flashes. Hot flashes and related symptoms represent a significant unmet, worldwide, healthcare need, not only in women after surgical or natural menopause, but also in breast and prostate cancer patients undergoing hormone suppression or ablation. Hot flashes occur in 65 ? 90% of women undergoing natural menopause and approximately 70 million individuals worldwide seek therapy each year. A hot flash is a sudden feeling of warmth that is generally most intense over the face, neck and chest as well as peripheral vasodilation leading to flush (reddening of the skin). The duration is variable but averages about 4 minutes. It is often accompanied by sweating. Although not life- threatening, hot flashes can have a detrimental effect on a woman's functional ability and quality of life. The physiological mechanisms leading to a hot flash episode are not known. Similarly, it is not known how the decreasing hormone levels that occur during the menopause transition lead to increased incidence of hot flashes and related symptoms. The only approved therapies for hot flashes are hormone therapy (HT) and a low dose form of paroxetine, an anti-depressant. HT is associated with severe health risks including development of heart disease, cancer, stroke and dementia. Paroxetine use is associated with suicidal thoughts and ideation as well as addiction. While there are no other FDA-approved alternatives, physicians often prescribe other anti-depressants, anti-psychotic agents and pain medications, all of which have significant side effects. Seeking less dangerous alternatives, many women turn to alternative therapies including nutraceuticals and acupuncture but none of these have proven to be effective in placebo-controlled trials. An effective, non-hormonal, non-anti-depressant, treatment for hot flashes and related vasomotor symptoms would be a welcome, novel and useful treatment modality. MenoGeniX is repurposing a naturally occurring human protein called granulocyte colony-stimulating factor (G-CSF) to treat hot flashes based on placebo-controlled phase 1 clinical trial data which showed that a single administration of G-CSF can lead to a rapid and significant reduction in hot flash frequency and severity in women with naturally-occurring and surgically-induced menopause. Women with surgically-induced menopause as well as African-American women responded especially well. In this phase 1 SBIR application, MenoGeniX is proposing a placebo- controlled, dose-range finding, phase 2a clinical trial to evaluate the efficacy and safety of G-CSF administered monthly to treat menopausal hot flashes. With a good safety record when used chronically to treat neutropenia, G-CSF may represent a valuable alternative for women with bothersome, moderate to severe hot flashes who are unwilling or unable to take HT or anti-depressants.
Hot flashes occur in 65 ? 90% of women undergoing naturally-occurring, as well as surgically- and chemotherapy-induced menopause with approximately 70 million individuals worldwide seeking therapy each year. The only FDA approved therapies are hormone therapy and an anti-depressant called paroxetine, both of which have life threatening side effects which discourage their use. MenoGeniX is developing a naturally occurring human protein called G-CSF to treat hot flashes. G-CSF may represent a valuable alternative for women with bothersome, moderate to severe hot flashes who are unwilling or unable to take HT or anti- depressants.
